This works describes a new and non-invasive way to simultaneously monitor an inflammatory response, lysosomal dysfunction, kidney and cardiovascular disease.  Fabry Disease is a condition where we cannot breakdown a glycolipid.  This builds up in the body causing kidney and/or cardiovascular damage. Plasma lyso-Gb3 is the general lipid biomarker used to monitor response to treatment but it does not tell us anything about what organs are affected or which systems are responding. Our simple, 10-minute, targeted proteomic urine test measures many biomarkers at once and allows us to monitor organ damage without the need for invasive or time consuming procedures. (By Dr Kevin Mills, https://jmg.bmj.com/content/early/2019/09/12/jmedgenet-2019-106030 )